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Introduction
Renal transplantation has experienced important modifica-
tions during the last two decades. Donor and recipient char-
acteristics have been modified during this period of time.
Donor age, a major determinant of graft outcome, has in-
creased as well as the proportion of donors dying of stroke.
Recipients are older, and their cardiovascular risk burden
has also steadily increased. On the other hand, new immu-
nosuppressants have allowed a dramatic reduction in the
prevalence of acute rejection. In this changing situation,
it is necessary to monitor how these modifications influ-
ence patient and graft survival [1]. Additionally, transplant
policies in different countries differ in many aspects. The
consequences of these policies on outcome are important
to understand since this knowledge is necessary to fine-
tune the organization of renal transplantation in the future.
Renal transplantation in Spain has some special charac-
teristics. The Spanish system has favoured local harvesting
and local implantation. This policy has been successful in
increasing the number of cadaveric donors. However, as a
consequence of this success, the number of kidney trans-
plants obtained from living donors is lower than in other
countries [2]. In order to monitor a time-dependent modi-
fication in donor and recipient characteristics and treat-
ment modifications in Spain, the Spanish Chronic
Allograft Dysfunction Study Group was created as a study
group of the Spanish Society of Nephrology in year 2000.
For this purpose, a detailed database was created, thanks to
an unrestricted grant from Wyeth Farma Spain (currently
Pfizer), and all Spanish adult transplant centres were invit-
ed to participate. Patients transplanted in 1990, 1994 and
1998 were considered for the present study and were fol-
lowed up until June 2001. The general results of this
study were published in 2003, and the particular aspects
of this cohort were published in Volume 19, Supplement 3
of Nephrology, Dialysis and Transplantation in 2004.
In 2003, it was decided to include the cohort of patients
transplanted in Spain in 2002, and all cohorts were fol-
lowed up until December 2005. The first publication de-
scribing risk factors associated with outcome in this
second phase of the study was recently published, in which
a novel score for mortality in renal transplant recipients be-
yond the first year was described [3].
In the present supplement, specific aspects regarding the
updated study are presented. The analysis has focused on
the evolution of treatment attitudes in Spain between 1990
and 2002. In this regard, the evolution of the use of statins
and its association with graft survival, death censored graft
survival, and patient survival have been analysed. Similar-
ly, in another article, the use of angiotensin-converting en-
zyme inhibitors or angiotensin receptor blockers and its
association with outcome are presented. Steroid withdraw-
al in Spain is also reviewed. Selection criteria for steroid
withdrawal are analysed, and the outcome after steroid
withdrawal is thoroughly described. The evolution of in-
duction therapy in Spain during the study period is also
reviewed, its indications and its relationship with outcome.
Additionally, other topics such as outcome in re-transplant
patients, relationship between new onset diabetes after
transplant and weight gain, outcome in hepatitis C-positive
recipients and factors associated with renal function decline
are analysed.
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